Novo Nordisk Heads to New Orleans With Pipeline Hopes as Headwinds Multiply
Novo Nordisk’s Wegovy loses CVS exclusivity, faces product-liability lawsuits over blindness risk, but a new Medicare program opens…
Novo Nordisk Heads to New Orleans with a Cleaner Competitive Field and a Pipeline to Prove
FDA rule targets cheap GLP-1 imitations, boosting Novo Nordisk as it prepares key CagriSema data at ADA. Stock…
Novo Nordisk Heads Into a Pipeline Double-Header That Could Redefine Its GLP-1 Franchise
Novo presents MASH, sleep apnoea, and CagriSema data at EASL and ADA, expanding GLP-1 platform. Stock up 16%…